Sugi Predict

Sugi Predict / Compounds / SCHEMBL716403

SCHEMBL716403

SCHEMBL716403

O=Cc1cn2cc(C(F)(F)F)ccc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.50
▸ ALDH1A1 P00352 4/20 0.50
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ HPGD P15428 2/20 0.50
▸ POLB P06746 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ GFER P55789 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50
▸ RCE1 Q9Y256 1/20 0.50
▸ MAPT P10636 1/20 0.42
▸ MCHR1 Q99705 9/20 0.39
▸ USP7 Q93009 1/20 0.38
▸ METTL3 Q86U44 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.35
▸ CLK2 P49760 1/20 0.34
▸ AHR P35869 1/20 0.34
▸ SCN5A Q14524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889270 0.78 PARP1 (0.39) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL869867 0.77 APP (0.43) KDM4EALDH1A1NPC1RAB9AMETTL3
SCHEMBL871995 0.75 NPC1 (0.50) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL19086907 0.74 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL16648467 0.74 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL4784975 0.74 RAB9A (0.51) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL12778283 0.74 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2NPC1HPGD
SCHEMBL11914801 0.74 PIK3CG (0.55) KDM4EALDH1A1SMN1; SMN2NPC1POLB
SCHEMBL14046264 0.74 PIK3CG (0.38) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL5773449 0.74 APP (0.43) KDM4EALDH1A1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040703-B1 DERIVATIVES OF 2-BENZOYL-IMIDAZOPYRIDINES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2009-10-21 — — EP claimed
US-20250376473-A1 PRMTS INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2025-12-11 — — US disclosed
EP-4549442-A1 PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 — — EP disclosed
EP-4549440-A1 CLASS OF PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 — — EP disclosed
CN-119552175-B PRMT5-MTA inhibitor 赛岚(杭州)生物医药科技有限公司 2025-04-29 — — CN disclosed
CN-119552175-A PRMT5-MTA inhibitor 赛岚(杭州)生物医药科技有限公司 2025-03-04 — — CN disclosed
CN-119562954-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-03-04 — — CN disclosed
CN-119487041-A PRMT5 inhibitor and application thereof 上海赛岚生物科技有限公司 2025-02-18 — — CN disclosed
CN-117800991-B PRMT5 inhibitor and application thereof 赛岚(杭州)生物医药科技有限公司 2025-02-14 — — CN disclosed
US-20240376126-A1 PRMT5 INHIBITOR AND THE USE THEREOF CYTOSINLAB THERAPEUTICS CO., LTD. (CN) 2024-11-14 — — US disclosed
WO-2024046512-A2 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2024-03-07 — — WO disclosed
WO-2024002376-A1 PRMT5 INHIBITORS AND USE THEREOF 上海赛岚生物科技有限公司 2024-01-04 — — WO disclosed
WO-2024002377-A1 CLASS OF PRMT5 INHIBITORS AND USE THEREOF 上海赛岚生物科技有限公司 2024-01-04 — — WO disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 — — US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 — — US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 — — US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 — — EP disclosed
US-20080171740-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION (US) 2008-07-17 — — US disclosed
EP-1793825-A2 CHEMCIAL COMPOUNDS SmithKline Beecham Corporation (US) 2007-06-13 — — EP disclosed
WO-2006036816-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-04-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885SMN1; SMN2 1051/4885
US-20080171740-A1 Chemical Compounds CXCR4, CCR5, CXCR3 KDM4E 4010/4885ALDH1A1 2769/4885SMN1; SMN2 4677/4885
US-20240376126-A1 PRMT5 INHIBITOR AND THE USE THEREOF PRMT5, PRMT1, PRMT6 KDM4E 40/4885ALDH1A1 4208/4885SMN1; SMN2 968/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP KDM4E 1907/4885ALDH1A1 504/4885SMN1; SMN2 1051/4885
US-20250376473-A1 PRMTS INHIBITOR AND USE THEREOF PRMT5, PRMT1, PRMT6 KDM4E 30/4885ALDH1A1 3032/4885SMN1; SMN2 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.